Ann: June 2014 App 4D Half Yearly Report and Financial Report, page-17

David, I think it's important to remember we are a company that in its life span is still an R&D company (opioids/dermatology/etc) transitioning to a commercial company (cosmeceuticals/vovaren/vital ET).
Ratio wise I see us still as 90% R&D and 10% commercial at best, and the commercial products of diclofenac are in its infancy in what most likely is a test and see scenario with Novartis.
Bio-elixia tic-toc tic-toc - with all publicity in the USA and some tvsn exposure, if some decent sales don't start FY 14-15 then ariverderci is say.
What I think is ideal is for POH to continue to seek arrangements similar to that of IAH.
Let external companies, promote, sell and make money for us.
IAH is also in its infancy, but by having a sole focus on itself and it's products are rapidly gaining momentum.
Let's keep it in perspective of where we are commercially.
It's a license which will shape the company this FY, IMO.